Preventive Effect of Pretreatment with Pitavastatin on Contrast-Induced Nephropathy in Patients with Renal Dysfunction Undergoing Coronary Procedure: PRINCIPLE-II Randomized Clinical Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Woong Chol | - |
dc.contributor.author | Kim, Minsu | - |
dc.contributor.author | Park, Sang Min | - |
dc.contributor.author | Kim, Byeong-Keuk | - |
dc.contributor.author | Lee, Byoung-Kwon | - |
dc.contributor.author | Kwon, Hyuck Moon | - |
dc.date.available | 2020-12-09T00:40:30Z | - |
dc.date.created | 2020-12-09 | - |
dc.date.issued | 2020-11 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/79212 | - |
dc.description.abstract | This study aimed to evaluate the efficacy of pitavastatin pretreatment on contrast-induced nephropathy (CIN) in patients with chronic kidney disease (CKD) after a coronary procedure. This was a prospective, randomized, double-blinded, placebo-controlled, multicenter clinical trial. All consecutive 70 patients with CKD (eGFR < 60 mL/min/1.73 m(2)) were enrolled and randomized into two groups. Group I consisted of patients who were treated with statins (pitavastatin 4 mg/day) for seven days before and three days after the procedure (n = 37, 52.9%), and group II consisted of patients who were treated with a placebo (n = 33, 47.1%). The primary endpoint was the incidence of CIN, and the secondary endpoints were the change in serum creatinine ( increment sCr) level and estimated glomerular filtration rate ( increment eGFR) after the procedure. The mean age of the patients (males, 74%) was 70.4 +/- 9.0 years. After the coronary procedure, the incidence of CIN was lower in group I than in group II, but the difference was not significant (5.4% vs. 9.1%, p = 0.661). The maximal increment sCr was lower and the maximal increment eGFR was higher in group I than in group II, but the difference was not significant (-0.11 +/- 0.53 mg/dL and -0.04 +/- 0.33 mg/dL, p = 0.678; 4.3 +/- 11.2 mL/min/1.73 m(2) and -2.9 +/- 20.4 mL/min/1.73 m(2), p = 0.161, respectively). This study showed the possibility of a clinical benefit of pretreatment with a high dose of pitavastatin for the prevention of CIN in patients with CKD after coronary procedure (ClinicalTrials.gov Identifier: NCT01871792). | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL MEDICINE | - |
dc.title | Preventive Effect of Pretreatment with Pitavastatin on Contrast-Induced Nephropathy in Patients with Renal Dysfunction Undergoing Coronary Procedure: PRINCIPLE-II Randomized Clinical Trial | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000593300700001 | - |
dc.identifier.doi | 10.3390/jcm9113689 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL MEDICINE, v.9, no.11 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85114283294 | - |
dc.citation.title | JOURNAL OF CLINICAL MEDICINE | - |
dc.citation.volume | 9 | - |
dc.citation.number | 11 | - |
dc.contributor.affiliatedAuthor | Kang, Woong Chol | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | pitavastatin | - |
dc.subject.keywordAuthor | contrast-induced nephropathy | - |
dc.subject.keywordAuthor | chronic kidney disease | - |
dc.subject.keywordPlus | HYPERCHOLESTEROLEMIA | - |
dc.subject.keywordPlus | PATHOPHYSIOLOGY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.